Isolation and characterization of anti c-met single chain fragment variable (scFv) antibodies

References

• Abdolalizadeh J, Nouri M, Majidi Zolbanin J, Barzegari A, Baradaran B, Barar J, Coukos G, Omidi Y. 2013. Targeting cytokines: Production and characterization of anti-TNF-α scFvs by phage display technology. Curr Pharm Des. 19:2839–2847.
   PubMed Web of Science ®Google Scholar
• Bendell J, Ervin T, Gallinson D, Singh J, Wallace J, Saleh M, Vallone M, Phan S, Hack S. 2013. Treatment rationale and study design for a randomized, double-blind, placebo-controlled Phase II study evaluating onartuzumab (Met MAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer. Clin Colo-Rectal Cancer. 12:218–222.
   PubMed Web of Science ®Google Scholar
• Carter P. 2001. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 1:118–129.
   PubMed Web of Science ®Google Scholar
• Eder J, Woude G, Boerner S, LoRusso P. 2009. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 15:2207–2214.
   PubMed Web of Science ®Google Scholar
• Edwardraja S, Neelamegam R, Ramadoss V, Venkatesan S, Lee S. 2010. Redesigning of anti-c-Met single chain Fv antibody for the cytoplasmic folding and its structural analysis. Biotechnol. Bioeng. 106:367–375.
   PubMed Web of Science ®Google Scholar
• Gao H, Guan M, Sun Z, Bai C. 2015. High c-Met expression is a negative prognostic marker for colorectal cancer: A meta-analysis. Tumour Biol. 36:515–520.
   PubMed Web of Science ®Google Scholar
• Gherardi E, Birchmeier W, Birchmeier C, Woude G. 2012. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 12:89–103.
   PubMed Web of Science ®Google Scholar
• Greenall S, Gherardi E, Liu Z, Donoghue J, Vitali A, Li Q, Murphy R, Iamele L, Scott A, Johns T. 2012. Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET. PLoS One. 7:e34658. doi: 10.1371/journal.pone.0034658.
   PubMed Web of Science ®Google Scholar
• Gupta P, Han S, Holgado-Madruga M, Mitra S, Li G, Nitta R, Wong J. 2010. Development of an EGFRvIII specific recombinant antibody. BMC Biotechnol. 10:72. doi: 10.1186/1472-6750-10-72.
   PubMed Web of Science ®Google Scholar
• He C, Ai J, Xing W, Chen Y, Zhang H, Huang M, Hu Y, Ding J, Geng M. 2014. Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells. Acta Pharmacol Sinica. 35:89–97.
   PubMed Web of Science ®Google Scholar
• Heo M, Kim S, Kim S, Kim Y, Chung J, Oh M, Lee S. 2006. Functional expression of single-chain variable fragment antibody against c-Met in the cytoplasm of Escherichia coli. Protein Express Purif. 47:203–209.
   PubMed Web of Science ®Google Scholar
• Jhanwar Y, Divgi C. 2005. Current status of therapy of solid tumors. J Nuclear Med. 46:141S–150S.
   PubMed Web of Science ®Google Scholar
• Jiang W, Martin T, Parr C, Davies G, Matsumoto K, Nakamura T. 2005. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol. 53:35–69.
   PubMed Web of Science ®Google Scholar
• Kim Y, Neelamegam R, Heo M, Edwardraja S, Paik H, Lee S. 2008. Improving the productivity of single-chain Fv antibody against c-Met by rearranging the order of its variable domains. J. Microbiol Biotechnol. 18:1186–1190.
   PubMed Web of Science ®Google Scholar
• Kwon Y, Smith B, Zhou Y, Kaufman M, Godwin A. 2015. Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment. Oncogene. 34:144–153.
   PubMed Web of Science ®Google Scholar
• Liu Z, Feng Z, Zhu X, Xu W, Zhu J, Zhang X, Fan Z, Ji G. 2013. Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL. Immunol Lett. 149:30–40.
   PubMed Web of Science ®Google Scholar
• Lu R, Chang Y, Chen M, Wu H. 2011. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials. 32:3265–3274.
   PubMed Web of Science ®Google Scholar
• Maniatis T, Fritsch E, Sambrook J, editors. 1982. Molecular cloning: A laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
   Google Scholar
• Martens T, Schmidt N, Eckerich C, Fillbrandt R, Merchant M, Schwall R, Westphal M, Lamszus K. 2006. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res. 12:6144–6152.
   PubMed Web of Science ®Google Scholar
• Maulik G, Shrikhande A, Kijima T, Ma P, Morrison P, Salgia R. 2002. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. 13:41–59.
   PubMed Web of Science ®Google Scholar
• Nahta R, Hortobagyi G, Esteva FJ. 2003. Growth factor receptors in breast cancer: Potential for therapeutic intervention. Oncologist. 8:5–17.
   PubMed Web of Science ®Google Scholar
• Nejatollahi F, Abdi S, Asgharpour M. 2013. Anti-proliferative and apoptotic effects of a specific anti-prostate stem cell single chain antibody on human prostate cancer cells. J Oncol. 2013:831–839.
   Google Scholar
• Prat M, Narsimhan R, Crepaldi T, Rita Nicotra M, Natali P, Comoglio P. 1991. The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int J Cancer 49:323–328.
   PubMed Web of Science ®Google Scholar
• Sadreddini S, Seifi-Najmi M, Ghasemi B, Kafil H, Alinejad V, Sadreddini S, Younesi V, Jadidi-Niaragh F, Yousefi M. 2015. Design and construction of immune phage antibody library against tetanus neurotoxin: Production of single chain antibody fragments. Human Anti-Bodies. 23:73–79.
   PubMedGoogle Scholar
• Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L. 2009. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One. 4:e7287. doi: 10.1371/journal.pone.0007287.
   PubMed Web of Science ®Google Scholar
• Sharifzadeh Z, Rahbarizadeh F, Shokrgozar M, Ahmadvand D, Mahboudi F, Jamnani F, Bakhtiari S. 2013. Development of oligoclonal nanobodies for targeting the tumor-associated glycoprotein 72 antigen. Mol Biotechnol. 54:590–601.
   PubMed Web of Science ®Google Scholar
• Sonoda H, Kumada Y, Katsuda T, Yamaji H. 2011. Effects of cytoplasmic and periplasmic chaperones on secretory production of single-chain Fv antibody in Escherichia coli. J Biosci Bioeng. 111:465–470.
   PubMed Web of Science ®Google Scholar
• Surati M, Patel P, Peterson A, Salgia R. 2011. Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther. 11:1655–1662.
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Bilchik A, Saha S, Turner R, Wiese D, Tanaka M, Kuo C, Wang H, Hoon D. 2003. c-MET expression level in primary colon cancer: A predictor of tumor invasion and lymph node metastases. Clin Cancer Res. 9:1480–1488.
   PubMed Web of Science ®Google Scholar
• Tao J, Xiang J, Li D, Deng N, Wang H, Gong Y. 2010. Selection and characterization of a human neutralizing antibody to human fibroblast growth factor-2. Biochem Biophys Res Commun. 394:767–773.
   PubMed Web of Science ®Google Scholar
• van der Horst E, Chinn L, Wang M, Velilla T, Tran H, Madrona Y, Lam A, Ji M, Hoey T, Sato A. 2009. Discovery of fully human anti-MET monoclonal antibodies with anti-tumor activity against colon cancer tumor models in vivo. Neoplasia. 11:355–364.
   PubMed Web of Science ®Google Scholar
• Watermann I, Schmitt B, Stellmacher F, Müller J, Gaber R, Kugler C, Reinmuth N, Huber R, Thomas M, Zabel P. 2015. Improved diagnostics targeting c-MET in non-small cell lung cancer: Expression, amplification, and activation? Diagn Pathol. 10:130. doi: 10.1186/s13000-015-0362-5.
   PubMed Web of Science ®Google Scholar
• Younesi V, Nejatollahi F. 2014. Induction of anti-proliferative and apoptotic effects by anti-IL-25 receptor single chain antibodies in breast cancer cells. Int Immunopharmacol. 23:624–632.
   PubMed Web of Science ®Google Scholar
• Zehnder-Fjällman A, Marty C, Halin C, Hohn A, Schibli R, Ballmer-Hofer K, Schwendener R. 2007. Evaluation of anti-VEGFR-3 specific scFv antibodies as potential therapeutic and diagnostic tools for tumor lymph-angiogenesis. Oncol Reports. 18:933–941.
   PubMed Web of Science ®Google Scholar
• Zeng Z, Weiser M, D’Alessio M, Grace A, Shia J, Paty P. 2004. Immunoblot analysis of c-Met expression in human colorectal cancer: Over-expression is associated with advanced stage cancer. Clin Exp Metastasis. 21:409–417.
   PubMed Web of Science ®Google Scholar
• Zhao A, Tohidkia M, Siegel D, Coukos G, Omidi Y. 2016. Phage antibody display libraries: A powerful antibody discovery platform for immunotherapy. Crit Rev Biotechnol. 36:276–289.
   PubMed Web of Science ®Google Scholar